Cargando…
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of EGFR is of major importance since the receptor influences many important tumor cell activities including tumor growth, neo-angi...
Autores principales: | Merlano, Marco, Occelli, Marcella |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376084/ https://www.ncbi.nlm.nih.gov/pubmed/18473010 |
Ejemplares similares
-
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009) -
Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018) -
Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013) -
Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021) -
Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)